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EVALUATION OF CHRONIC KIDNEY DISEASE BY USING VISUAL
EVOKED POTENTIAL AND UREMIC MARKERS
Abstract:
BACK GROUND:Chronic Kidney Disease is often unrecognized health
problem due to less awareness,less health care facilities.Due to its progressive
and irreversible course  it may presents with serious complications involving all
systems including the central nervous system of our body.
AIM AND OBJECTIVE:  The  aim of the present  study was to “evaluate the
involvement of central nervous system(CNS) in Chronic kidney disease (CKD)
patients  by doing Visual Evoked Potentials(VEP) and the estimation  of  blood
levels of uremic markers (Uremic neurotoxins)  like Blood Urea, Serum
Creatinine. Serum Parathyroid hormone(PTH)  in comparison with age matched
controls”.  The objectives of the study were “ to determine  the subclinical
involvement  of  central  nervous  system  in  CKD  patients    by  doing  Visual
Evoked  Potentials  and  compare  it  with  controls,to   assess  the  uremic
neurotoxin’s role in uremic encephalopathy by measuring the blood levels of
uremic markers(uremic neurotoxins) like Blood Urea,Serum Creatinine,Serum
Parathyroid hormone  in  CKD patients and compare it with controls,to find out
the most vulnerable group of CKD patients by comparing the VEP parameters
and blood levels of uremic markers(uremic neurotoxins) among the two CKD
groups (CKD3-5 on medical therapy, CKD5D on dialysis and to  find the
correlation between  the Visual Evoked Potential(VEPs) parameters and blood
level of   uremic marker in  Chronic Kidney Disease(CKD)  patients”.
MATERIAL AND METHODOLOGY:60 diagonsed as CKD (30-CKD3-
5,30-CKD5D) were recruited  from Department of Nephrology ,Stanley medical
college,Chennai.30 normal subjects were recruited from Master health check-
up, Stanley medical college,Chennai.Ethical committee approval was
obtained.Informed and wtitten consent was obtained.After explaining the
procedure ,VEP recording was done with the RMS Polyrite apparatus.The blood
investigation done for the measurement of uremic markers.
RESULTS: Means, standard deviations, chi square and 'p'  values were
calculated by One way ANOVA and ‘t’ test. Chi-square  test was used to
experiment the importance of disparity  among the  consolidated (quantitative)
variables.Prolonged latencies with highly significant p-value (p<0.0001) of all
VEP parameters and reduced amplitude with significant p-value (<0.05) was
noticed. Elevated blood levels of all uremic markers was noticed.This altered
variables was higher among CKD3-5 with significant p-value(p<0.05) in
comparison with CKD 5D. Correlation was noticed but not significant between
VEP parameters and blood levels of uremic markers.
DISCUSSION:The altered parameters of VEP and Uremic markers  may
predict the subclinical involvement of central nervous system involvement  in
CKD patients.
CONCLUSION:In order to reduce the morbidity and mortality in CKD patients
,VEP recording and the estimation of blood levels of uremic markers may used
s a screening  tool to identify the subclinical involvement of central nervous
system in future.
KEY WORDS:Chronic kidney disease, Uremic markers, Visual evoked
potentials.
1. INTRODUCTION
Chronic kidney disease (CKD) is a common disorder and is an often
unrecognized health problem. People with CKD  either remain undiagnosed
because of absence of  definite signs and  symptoms or they  present themselves
in a very late stage with complications . The central nervous system(CNS)
involvement is the most dreadful complication.
The word chronic kidney disease  refers to the development of  gradual
irreversible decline in  functioning nephron, and characteristically belongs to
final  stages  of  CKD1. The term uremia refers to the symptomatic stage of
patients with chronic kidney disease2.
The  term   ESRD  (end-stage  renal  disease)  stands  for  a  phase  of  CKD
with  the  accumulated uremic toxins, and many electrolytes  which are usually
removed by the functioning  kidneys leading  to  the uremic syndrome.
Mortality in CKD is due to   the  buildup  of  toxic  excretory products that   are
not   cleared   by  any  form  of   renal  replacement  therapy  like  dialysis  or
transplantation of kidney.
Accumulation of uremic toxin have harmful  effects on  all  the systems,
the severity pertains much to the central nervous system (CNS).3-7 Though the
synaptic dysfunction and neuronal axonal degeneration is found to be the
pathological basis of  the neural symptoms, the exact basis for CNS abnormality
is  still vague and unclear. It has been assumed that the accumulation of organic
and inorganic substances such as urea, creatinine, uric acid, carnitine
polyamines, indolic acid, myoinositol, guanidine compounds sulfate and
phosphate, hippurate, acetone, glucuronate, hypocalcemia induced secondary
hyperparathyroidism  have an effect on the  central nervous system.
The worldwide prevalence of CKD is estimated to be 8–16%. In  India
given its population in billions ,because of the scarce resources,
disproportionate patient –health care system and cost expensive treatment, the
patients with CKD does not receive sufficient treatment facilities. Though  the
exact level of the problem of chronic kidney disease(CKD) or end-stage renal
disease(ESRD) is not recognized, the crude and age- accustomed ESRD
incidence rates by  Indian population-based study was found to be 151 and 232
per million population, correspondingly.8,9 It is anticipated that 1,00,000 new
patients of end stage renal disease (ESRD) go into renal replacement therapies
yearly in India10.
Owing to the lack of community based screening programmes, lack of
knowledge of the  disease, among people and Health personals, the incidence
rate of CKD with mortality is still  undertermined cause  in addition to
environmental factors. Renal transplantation is found to be  the correct line of
management  because of late presentation and  it is dependent on living donors
which is not a possibility.
In addition to the above factors some other factors like less  healthcare
availability, leads to a failure of introducing  appropriate precautionary
procedures. Kidney failure is generally more  progressed  by the time patients
consult  a  physician  and  they  may  go   to  a  worst  state  with  major  side  effects
including  neuropathy  and  multiple organ failure and  necessitating an urgent
dialysis. It has been proved that management with any modality like medical
management or renal replacement therapy either dialysis or renal transplant  can
stop or holdup the sequence of CKD.
The Indian government has integrated  care for renal disease in its 12th 5-
year plan cycle, and is at present in the progression of mounting a structure for
both  dialysis and transplantation.
Preventive nephrology stress early detection of  renal disease and the
organization of procedures to delay its evolution to final stage. Treatment by
any modality should start before the   commencement of harmful complication.
The dangerous complications of progressive CKD involving central nervous
system like uremic encephalopathy can be predicted earlier  by the alterations in
parameters of Visual Evoked Potential(VEP)11-16
Because of  the  progressive and the irreversible nature of the disease in
CKD it is advisible  to evaluate the complications as early as possible by both
VEP parameters and  the estimation of  blood levels of uremic neurotoxins
(uremic markers).
The possible uremic markers could be blood urea, serum    creatinine,
serum   uric  acid,  serum  parathyroid  hormone  as  they  can  sense  the  CNS
complication  earlier along with  the abnormalities with  visual evoked
potentials  in CKD patients.
The Visual Evoked Potential is an uncomplicated, easy, non-invasive test
that may predict the involvement of central nervous system, like  uremic
encephalopathy at the  earliest  by the altered parameters.
Hence this  research study was carried out to enlighten the consequences
of altered Visual Evoked Potentials (VEP),Uremic markers in CKD stage 3-5
and CKD 5D (on Dialysis) in order to detect the serious complication as early as
possible and start  any form of replacement  treatment  therapy. This might be
helpful to provide early intervention  in order to prevent morbidity and
mortality.
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2.11. Literatures
2.1. HISTORICAL ASPECTS OF KIDNEY
1913:  John Abel, a well-known pharmacologist at John  Hopkins
University published an editorial regarding hemodialysis among animals to
eliminate toxins  that were accumulated in the blood.
1933: The foremost documented human cadaveric kidney transplant was
done  in   Russia.
1936: UVoronoy (Starzl   TE, 1990) did a primary human kidney
transplant  from an allograft.
1943:  The young  Dutch physician Dr. Willem Kolff is thought  to be
the father of dialysis  who  created the initial drum dialyzer  (artificial kidney)
which is still the basis behind current dialysis.
2.2.  HISTORICAL ASPECTS OF VISUAL EVOKED POTENTIAL
(VEP)
1934: With the light stimuli Adrian and Matthew observed probable
alteration  of the occipital EEG.
1961: The primary categorization of occipital EEG components was
urbanized by Ciganek.
1965:  The  checkerboard  type   of   visual   stimulation  was  handled  by
Spehlmann to  illustrate VEPs in human beings .
1972: The initial quantifiable research was concluded by   Halliday and
colleagues in subjects with retrobulbar neuritis.
2.3. PHYSIOLOGICAL ANATOMY OF KIDNEY
The two kidneys, which weigh about 150 gms each in adults are
positioned   in  the  superior  dorsal   part   of  the  abdominal   cavity  retro
peritoneally, on both side of the vertebrae. On vertical section, it  shows cortex
which is situated  outer and  inner placed medulla which have  10-12 pyramids
ending in the renal papillae17.Papillae  in turn divide into calyces  which come
out all the way through the renal pelvis of kidney to the broad end of the ureter.
The nephron is the functional component of  kidney. There are
approximately 1.3 million nephrons in each kidney18 (Fig:1). The different parts
of the nephron are, Bowmans’s capsule with tuft of capillaries, the proximal
convoluted tubule (PCT), the loop of  Henle, the distal convoluted tubule (DCT)
and the collecting tubule (CT).
Fig : 1 -  STURCTURE  OF  NEPHRON
2.4 FUNCTIONS OF THE KIDNEY
The ultrafiltration of blood, reabsorption, and secretion of substances are
the major functions of kidney. Filtration, which occur at the renal corpuscle is
the ultrafiltration which means free from huge proteins and cells of the blood.
Reabsorption is the process by which water and solutes move into the blood.
Secretion is the process by which substances are passed out from the blood into
the urine. The two major functions of kidney are
A. EXCRETORY FUNCTION
B.  NON- EXCRETORY FUNCTION
2.4 A. EXCRETORY FUNCTION
Normally the functioning kidneys excrete a range of metabolic waste
products formed from protein catabolism such as, urea and uric acid - the
nitrogenous waste products. The major function of the kidney is the formation
and concentration  of  urine which is   mainly due to the  hair  pin model  of  the
tubules, the permeability of the descending limb and  impermeability of the
ascending limb of  loop of Henle to water, active  transport of solutes out of  the
ascending loop, countercurrent multiplication system, countercurrent exchange
by the vessels.
2.4. B. NON-EXCRETORY FUNCTIONS
I. Acid-base homeostasis
II. Osmolality regulation
III. Blood pressure regulation
IV. Hormone secretion
I. ACID-BASE HOMEOSTASIS
The kidney can maintain the acid-base balance by reabsorption of
bicarbonate (HCO3) from the urine, and excretion of hydrogen(H+ ions).
II.OSMOLALITY REGULATION
In  response to raised  plasma osmolality, which is sensed  immediately
by the hypothalamus, inturn  triggers the posterior pituitary gland to synthesize
antidiuretic hormone (ADH), ADH  act  on the  principal cells  of the collecting
ducts  which subsequently  move aquaporins to the apical membrane, allowing
water to be reabsorbed into the vasa recta, thereby  raising  the plasma volume
of the body and  creating a concentrated urine.
III. BLOOD PRESSURE REGULATION
The kidneys play a major role in  long-term  control  of  blood pressure
predominantly via  the  renin-angiotensin system.
IV. HORMONE SECRETION
The functioning  kidneys secrete a range of hormones, such as
? Erythropoietin which  causes  erythropoiesis  in the bone marrow.
? 1,25 dihydroxycholicalciferol, the active type of vitamin D, cause
absorption of calcium from the intestine and the  reabsorption of
phosphate from the renal tubules19.
? Renin
? Synthesis of prostaglandins.
? Formation of  tissue  Kallikerin.
?
2.5. CHRONIC  KIDNEY DISEASE –  A   REVIEW
Chronic kidney disease (CKD) is  a  medical  state in which the kidneys
do   not  succeed  to  sufficiently  remove  waste  products  from  the  blood  by
filtration1. CKD is characterized by a decline in glomerular filtration
rate(GFR).This is identified by the reduced  ability or total failure to urinate and
by the estimation of  waste products (creatinine or urea) in the blood.
2.5.1. PATHOGENESIS  OF  CHRONIC KIDNEY DISEASE
The pathogenesis of CKD include
(1) Initial insult particular to the primary cause (e.g., of inflammatory
intermediaries and immune complexes in some forms of  nephritis or
toxins  induced   interstitial kidney  diseases.
(2) Another one is a progressive effect   due to hyperfiltration and
hypertrophy of the residual functioning nephrons, leading on to a
progressive reduction in nephron number, (Fig 2)regardless of primary
cause mediated by cytokines, growth factors, vasoactive hormones.
Finally, these leads to sclerosis and failure of the left over nephrons.
Augmented role of the renin- angiotensin pathway found to be the basic
pathology behind the above two mechanisms. Recently, transforming
growth factor (TGF-?) appeared to have a role in progressive damage to
the  kidney1.
Fig : 2 –NORMAL AND HYPERINFILTRATING GLOMERULUS
2.5.2. SIGNS AND SYMPTOMS OF CHRONIC KIDNEY DISEASE
Stages 1-3 of CKD patients usually do not present with any symptoms. If
they become symptomatic, it is mandatory to diagnose the degree of insult to
the kidney. A clinician’s interpretation is necessary if patients present with the
following signs and symptoms:
? Fatigue
? Weakness of muscles
? Muscle cramps
? Edema  - swollen  feet and ankle
? Puffiness around the eyes
? A need to pass urine more often than normal
? Pale due to anemia
? Metallic taste in mouth
? GIT (gastrointestinal tract)involvement: Anorexia, vomiting, diarrhea.
? Shortness of breath
?  Dizziness & Trouble Concentrating
? Skin appearance: Dry skin, ecchymosis and pruritis
? Augmented somnolence20
2.5.3. CAUSES OF CHRONIC KIDNEY DISEASE
1. Diabetes mellitus
2. Hypertension.21
3. Polycystic kidney disease
4. Immunologic - Polyarteritis Nodosa, Glomerulonephritis, Lupus
5. Nephrotoxins
6. Drugs –Non steroidal anti-inflammatory drugs (NSAID)22
7. Infectious causes - Tuberculosis, Pyelonephritis, Hantavirus23
8. In people of African basis, the APOL1 gene has been expected as a
considerable genetic risk24-26
2.5.4. CHRONIC KIDNEY DISEASE- STAGES
On the basis of current guiding principle of the National Kidney
Foundation [Kidney Dialysis Outcomes Quality Initiative (KDOQI)], Clinical
Practice Guidelines for Chronic Kidney Disease1 (CKD) stages are distinct
according to the GFR estimation
GFR estimation was done using these following formulas:
? The Modification of Diet in kidney disease
Estimated Glomerular Filtration Rate=1.86×(Pcr) –1.154×(age) –0.203
multiply by 0.742 for females.
? Cockcroft- Gault formula(usually followed)
Estimated GFR=(140-age) × weight in kg divided by 72xPcr multiply by
0.85 for females
Where,
Pcr- Concentration of Serum Creatinine
GFR- Glomerular filtration rate
STAGE GFR ( mL/min per 1.73 m2)
0 >90a
1 90b
2 60–89
3 30–59
4 15–29
5 <15
a - Risk factors like older age, Diabetes Mellitus (DM) , family history of  any  kidney  disease,
African ancestry, Systemic hypertension, Autoimmune disorders , a preceding incident of acute
kidney damage.
b  - Associated with established kidney harm (e.g., constant proteinuria, nonstandard urine
and blood  biochemistry, unusual urine sediment, atypical imaging studies).
The usual yearly noticeable turn down in Glomerular filtration  rate  from
thehealthy individuals is  1ml/min/year/ 1.73 m2, getting an average  value of 70
ml/min/1.73 m2 at the 70 years of age. The  average  GFR is lesser in females
compared to male.
2.6. PATHOPHYSIOLOGY OF UREMIA
Uremia  explains  the  last  stage  of  progressive  renal  failure   and  the
consequential multiorgan failure. It results from buildup of metabolites of
proteins and amino acids and associated failure of renal catabolic, metabolic,
and endocrinologic course. No solitary metabolite has been recognized as the
exclusive source of uremia. Uremic encephalopathy (UE) is one of  the
complication of renal failure (RF).24 Several harmful toxic substances like urea
and creatinine have been found to be accumulated  in  uremic syndrome. Other
nitrogenous waste products like guanido compounds, polyamines, benzoates,
products of nucleic acid metabolism, urates, hippurates, uric acid, myoinositol,
phenols and indoles are also involved. In addition, plasma  estimation  of
substances  such  as insulin, prolactin, glucagon,  parathyroid hormone (PTH),
and sex hormones are altered due to urinary retention and reduced degradation.
Finally inflammation is also linked with progressive renal  failure associated
with elevated C-reactive protein. As a whole, the pathophysiology of the uremic
syndrome can be separated into  three phases of dysfunction:
? The  toxins  that are usually excreted by the kidneys accumulate in blood.
? There is failure of other renal functions like homeostasis  of fluid and
electrolytes and hormonal regulation.
? Progressive nutritional and vascular problems in account for systemic
inflammation1.
2.7. UREMIC  BIO-MARKERS (UREMIC NEUROTOXINS)
A. Urea
B. Creatinine
C. Parathyroid  hormone (Calcium, Phosphorous homeostasis)
2.6.A. UREA
It is  the  product of protein metabolism. It is generally excreted in the
urine. A raised  level of urea  denotes either renal dysfunction or dehydration.
2.6.B. CREATININE
 It  is an  intermediatry  product  formed  by the muscles . A raised level
of urea and creatinine indicates renal dysfunction. Among these two, estimation
of serum creatinine is  considered as a best marker and also used for the
staging. Goltch et al declared that the blood level of uremic markers like urea
and creatinine  has been used as an  indicator of uremic retention and its
elimination is straightforwardly linked with survival of the patients 28-30.
2.7. PARATHYRPOID HORMONE:
SECONDARY HYPERPARATHYROIDISM (SHPT)
1. INTRODUCTION
2. PATHOPHYSIOLOGY
2.7.1. INTRODUCTION
Chronic Kidney Disease (CKD) leads to reduction in phosphorus
excretion and hyperphosphatemia, vitamin D deficiency and hypocalcemia,
which inturn leads on to Secondary Hyperparathyroidism (SHPT).31  In  recent
times, the increase in  fibroblast growth  factor-23  (FGF-23) in CKD patients
due to phosphorus retention, has been found to  increase the calcitriol synthesis
which in turn leads to augmented PTH32. SHPT remains unrecognized and
under-diagnosed at prior stages of CKD. SHPT may be challenging to dietary/
dialytic /medical treatment and may continue even subsequent transplantation.33
2.7.2. PATHOPHYSIOLOGY OF SECONDARY
HYPERPARATHYROIDISM
There are four parathyroid glands situated in the neck. It synthesises a
polypeptide hormone parathyroid hormone (PTH), that maintain the accurate
equilibrium of serum calcium and serum phosphorous in the body. The entire
molecule is made of a series of eighty four amino acids.  SHPT seen in CKD is
due to excess synthesis of this hormone as a consequence of reduced functional
capacity of kidney.34
A. CALCIUM METABOLISM
The active form of Vitamin D3 (calcitriol) synthesized in kidney
combines  with vitamin D receptor (VDR)32. Vitamin D3 reduces the production
of parathyroid hormone (PTH) either by parathyroid VDR stimulation or by
increased activity of the intestinal VDR which  in turn ultimately leads to the
increased  absorption of calcium and increased serum calcium.36,37
          Due to kidney failure, there is a turn down of renal 1?-hydroxylase action
that is responsible for the ultimate hydroxylation reaction in   the synthesis  of
calcitriol. Due to the progressive nature of CKD, 1?-hydroxylation carried out
by kidney is reduced, leading to reduced synthesis of active form of vitamin D3
and increased PTH levels.38
         Decreased active form of vitamin D3 leads to reduced calcium absorption
from intestine. This  hypocalcemia  in turn leads to  secondary
hyperparathyroidism early in CKD39,40
B. PHOSPHORUS METABOLISM
In progressive CKD, there will be a noticeable alteration in the excretion
of  phosphorus ion. Initially,  functioning  nephrons work in excess in order to
compensate for the damaged, non-functioning nephrons. With  progression of
the disease this compensatory  mechanism  fails leading to hyperphosphatemia.
Secondary Hyperparathyroidism is due to hypocalcemia in progressive
CKD. In the serum, as the levels of one or both ions (calcium or phosphorous)
increases, there is more chance  for an ionic bond to form, leading to an
insoluble complex. Therefore, PTH synthesis  and release   may be motivated by
hypocalcemia, hyperphosphatemia, and vitamin D deficiency.41,42
2.8. MECHANISMS UNDERLYING UREMIC
ENCEPHALOPATHY
Signs and symptoms of encephalopathy include headache, asterixis,
visual abnormalities, chorea, tremor and seizures, mild sensorial clouding to
delirium uremic twitch convulsion and even coma43.  Both  forms the  acute or
chronic kidney disease may lead to uremic encephalopathy but along with acute
kidney failure(ARF) the signs and symptoms are  added up and steps forward
very  speedily.44,45 Yet in  CKD  patients who are neurologically asymptomatic,
unnatural cognitive involvement can be disclosed by event-related potentials.
2.8.1. PATHOPHYSIOLOGY OF UREMIC ENCEPHALOPATHY
The pathophysiology of uremic encephalopathy is vague, but various
factors have been recognized.46
A. Hormonal disturbances
B. Accumulation of metabolites
C. Oxidative stress
D. Disparity in excitatory and inhibitory neurotransmitters.
A. HORMONAL DISTURBANCES
Serum  estimation  of numerous substances like  glucagon , gastrin
prolactin, growth hormone ,parathyroid hormone, thyrotrophin, insulin and
luteinizing hormone are  raised  in  patients with kidney failure.48 Heath et al
noticed the significant   role  of   PTH(Parathyroid hormone) in the progress of
centrol  nervous system uremic   encephalopathy th49,50 In chronic kidney
disease(CKD), PTH level is prominently elevated with associated raised
calcium level in the cerebral cortex. This hypothesis is evidenced by a study
which confirmed  the irregularity of brain calcium content in dogs with renal
failure that are inhibited by parathyroidectomy, so these alterations appear to be
PTH-dependent.51
B. ACCUMULATION OF METABOLITES
Chronic kidney disease(CKD) leads to the accumulation of a range of
uremic toxins, like Urea, creatinine, guanidine, guanidinosuccinic acid (GSA),
and methylguanidine (MG).53
C. OXIDATIVE STRESS
Reactive oxygen species (ROS) are measured to be one of the significant
mediators of the pathophysiology of uremic encephalopathy. Numerous studies
illustrated that these toxic substances generate a inflammatory reaction in CKD
via the creation of a disparity between  raised production of ROS and imperfect
or reduced antioxidant capacity52
D. DISPARITY IN EXCITATORY AND INHIBITORY
NEUROTRANSMITTERS
             Chronic kidney disease(CKD) also leads to biochemical changes and
metabolic derangements which may be the cause for the behavioral deficits54-56
Disparity by means of raised levels of excitatory N-methyl-d-aspartate
(NMDA)  receptors   and   simultaneous  hang-up  of  inhibitory  GABA(A)
neurotransmitters have been anticipated as fundamental  cause.Recent studies
suggested that creatinine may operate as aggressive opponent at the
neurotransmitter appreciation location of the GABA-A receptor57,which was
also exposed in several extra endogenous GCs with convulsive action.58-60
2.9. HAEMODIALYSIS
1. DEFINITION
2. PRINCIPLE
3. TECHNIQUES-
1. An intravenous catheter -Non-tunnelled, tunneled
2. An arteriovenous fistula (AV)
3. A synthetic graft.
4. TYPES:
1. Conventional hemodialysis
2. Daily hemodialysis
3. Nocturnal hemodialysis.
5. COMPLICATIONS - Immediate & Late
6. PRECAUTIONS TO AVOID SIDE EFFECTS
7. ADVANTAGES AND DISADVANTAGES
8. HAEMODIALYSIS MACHIENE
2.9.1. DEFINITION
One among the three modalities of replacement therapies for kidney
failure is hemodialysis. Hemodialysis (also Haemodialysis-HD) is a technique
that is used in kidney failure individuals to attain  the  elimination of  metabolic
intermediatary  products like urea, creatinine and free water from the blood .
The  remaining  modalities are peritoneal dialysis and  kidney transplantation. It
can  be  carried out as an outpatient remedy or inpatient therapy.61
2.9.2. PRINCIPLE
It involves  the  passage of solutes via  a semi permeable membrane
(Fig3). It  make use of counter current flow, which preserve the concentration
gradient across the membrane and increases the effectiveness of the
haemodialysis.
Fig : 3 - SCHEME OF SEMIPERMEABLE  MEMBRANE
red = blood, blue = PD fluid yellow = membrane
2.9.3. TECHNIQUES
There are 3 primary techniques  applied  to achieve way in to the blood62 .
A. Catheter
B. Arteriovenous  fistula (AV)
C. Arteriovenous synthetic graft.
A. AN  INTRAVENOUS  CATHETER
It is occasionally named a CVC (Central Venous Catheter) made upof  a
plastic  one   had two lumens  which  is  introduced  through  a greater vein
(generally the  inferior vena cava, the femoral vein and  the internal jugular
vein)  to  permit  great  stream  of   blood  to  be   removed  from  one   side  of  the
lumen,  to  go  into  the  dialysis   machine  ,  and  to  come  back  by  the  use  of  the
additional lumen.
They  are generally set up in two common type
? Tunnelled
? Non-tunnelled.
NON-TUNNELLED
This type is used only for temporary use, mostly for single setting of
dialysis or may be used for 10 days. The point of introduction and the outlet site
was the same in this type.
TUNNELLED
It involves a lengthy type of catheter. There was some distance between
the summit point and the outlet point. This is frequently positioned in the neck
(summit of introduction is at internal jugular vein) and the chest wall was the
outlet site. They are used frequently.  In addition it acts as a barrier to attack
microbes.
B. AV (ARTERIOVENOUS) FISTULA
It is a most acceptable method. An artery and a vein  are communicated
via an anastomosis that bypasses the capillaries to create a fistula (Fig 4). Blood
flows speedily in the course of the fistula.
FIG - 4 - ARTERIO VENOUS (AV) FISTULA
LOCATION OF FISTULA
Fistulas are frequently created in arm. It acquires 4–6 weeks  time for the
fistula to mature. The usual sites  may be
a. The hand at the level of the snuffbox
b. The forearm - radiocephalic fistula or Brescia-Cimino fistula in which
the radial artery is joined to the cephalic vein.
c. The elbow - A brachiocephalic fistula.
d. At  the level of groin .
METHOD  OF  FISTULA  OPERATION
Two needles are introduced  into the fistula, one to withdraw the blood
and another one to push back blood.
C. AV (ARTERIOVENOUS) GRAFTS
A synthetic material is  used as a  graft  to join the artery and vein (Fig 5).
It matures very quickly.
FIG : 5 -ARTERIO VENOUS ( AV GRAFT)
2.9.4. TYPES OF HEMODIALYSIS
A. Usual, regular type (Conventional ) of  hemodialysis
B. Daily hemodialysis
C.  Nocturnal hemodialysis.
A. USUAL, REGULAR  TYPE  OF  HEMODIALYSIS
? It is regularly carried out as  thrice in a  week nearly three to four   hours
during each session.
? The  kidney failure individual's blood is drained away all the way via the
tube at a speed of 200-400 ml/min.
? The blood is first to passed  via the dialyzer, and  then  it is  passed back
into the  individual's  circulation via one more tube .
? The  blood pressure is strictly monitered, and if it is reduces, or if the
patient had some other signs of low blood volume like nausea, the
dialysis attendant can run more fluid all the way through the machine.
?  With this procedure, the  subject's whole volume of blood   nearly  5000
ml  pass throughout the  apparatus  once in fifteen minutes.
B. EVERY DAY HEMODIALYSIS
? It is usually  carried out  at  home.
?  It is more placid.
?  It  needs  more frequent procedures.
? This is  usually carried out with  catheters very easily, but  difficult with
AVF or grafts.
?  It is usually lasts   for  two  hours per each session, six days  in  a week.
C. NOCTURNAL HEMODIALYSIS
? It is analogous to usual  hemodialysis
? It is done 3-6 nights in  a week and lasting  for about  6-10 hours per
sitting while  the  subject  sleeps.63
2.9.5. COMPLICATIONS OF HAEMODIALYSIS
A. IMMEDIATE
B. LATE
C.
A. IMMEDIATE COMPLICATIONS
? Too much removal or too rapid removal leads to fatigue, reduced blood
pressure, leg-cramps ,headaches, chest pains, , nausea.
? Sepsis
? Infection of the heart valves  leading to endocarditis.
? Infection affecting the bones --osteomyelitis.
? Bleeding can also occur
? Heparin allergy is a  rare problem, that may lead to reduced platelet
count.
B. LATE  COMPLICATIONS
? Amyloidosis,
? Neuropathy
? Heart  disease. Due to excess fluid  accumulation  in  these  subjects.
2.9.6. PRECAUTIONS TO AVOID SIDE EFFECTS
? Fatigue, reduced blood pressure, leg-cramps , chest pain, nausea. – Can
be minimized by restraining fluid ingestion or increasing the frequency of
dialysis.
? Infection can be diminished by sticking  to  the infection control.
? Bleeding  as a consequences of dialysis   may vary according to the kind
of   modality we use.  By  following  careful  ,  finest  method ,it  may  be
reduced .  Even in some patients    this  procedure may done without   the
use of anticoagulant  substances.
2.9.7. ADVANTAGES AND DISADVANTAGES
ADVANTAGES
? Less mortality rate
? Minimal dietary limitation
? Enhanced solute  removal result for the  everyday haemodialysis
? Enhanced acceptance and fewer  side effects with extra recurrent
dialysis64
DISADVANTAGES
? Needs   always  some person’s support.
? Needs   extra  equipment  like  superior  water system  and  the provision
of  excellent electrical power.
? Needs  consistent machinery.
? This practice is complex and  needs  additional awareness.
? More expenditure had to be spent for the maintenance of the equipment.
2.9.8. HAEMODIALYSIS  MACHINE
This apparatus  propel the  subject's blood  via the dialyzer machine (Fig
6,7).  The latest apparatus  are extremely programmed and constantly check an
arrangement  of   some  features  like  analysis  of  the  dialysate  for  evidence  of
blood leakage, blood and dialysate flow rates, temperature,  pH, dialysis
solution conductivity, and the existence of air. Anything that is changed from
the normal value generates an alarm to aware paramedical staffs who is
supervising the procedure.
FIG : 6 -HAEMODIALYSIS  MACHINE
FIG:7-SCHEMATIC OF A HEMODIALYSIS CIRCUIT
2.10. VISUAL  EVOKED  POTENTIALS
2.10.1.DEFINITION OF  EVOKED POTENTIAL
An evoked potential or evoked response is  a  type  of  electrical response
documented from the human as well  as  from  the animal’s  nervous system  in
response to a stimulus.
Visual evoked potentials (VEP) are electrical response documented from
the vertex in reply to visual stimuli65. It represents the gathering reaction of the
cortical and probably subcortical areas. A normal cortical response is recorded
when the entire visual pathway is normal.
2.10.2. ANATOMICAL  BASIS OF VISUAL PATHWAY
The  retina  has  ten  layers  (Fig  8).  The  outermost  layer  is  the  pigment
epithelium.  The  rods  and  cones  lie  next  to  this  layer.  They  synapse  with  the
inner nuclear or bipolar cells, which  inturn project to the ganglion cell layer.
The axons of the ganglion cells form the optic nerve. The rods and cones are the
receptors that are stimulated by the  light mpulses and the information is
conveyed through the bipolar and  ganglion cells via optic nerve to the lateral
geniculate body via the optic chiasma, which in turn project to the visual cortex
through the optic radiation.
FIG: 8-LAYERS OF RETINA
2.10.3. PHYSIOLOGICAL  BASIS  OF  VEP
The P100  waveform of  VEPs is generated in the occipital cortex by the
activation of the primary visual cortex and activation of areas surrounding the
visual cortex by thalamocortical fibres (Fig 9).The retinal ganglion cell are of
three types: X,Y and W. The  X cells are small ganglion cells that mediate the
function of cone systems. They have small diameter axons and small receptive
fields. They are present in the central visual field and exhibit lateral inhibition.
They provide the substrate for pattern VEPs via the geniculate pathway. The Y
cells are large ganglion cells that mediate functions of rod system. They have
large  diameter  axon  with  a  large  receptive  field.  They  are  present  in  the
peripheral visual field and grant things via the  extrageniculate pathway  for
flash VEPs .It primarily represent the motion originating in the central part of
visual  pathway,  which  is  linked  to  the  exterior  of  the  occipital   cortex.  The
central part of retina (fovea centralis) has greater cortical illustration in the
visual cortex and events in the central visual field magnify the VEPs.
FIG:9 -VISUAL PATHWAY
2.10.4. METHODS  AND INSTRUMENATION
A. BASIC INSTRUMENTATION FOR DATA ACQUISITION
AMPLIFERS
Instrument  must  be with amplitudes down to 0.1 micro volts and band
with from below 1Hz to 10KHz.The impedance of electrodes should be below
5k?.
B. FILTERS
Low cut filters at 1-3Hz and high cut filter at 100-300Hz are available.
The filter setting should be kept constant.
C. ELECTRODES
These are fixed to the forehead & scalp by paste .It is necessary to check
the impedence of each electrode.
D. STIMULATORS
They are the basic part of the apparatus. The stimuli are coordinated to
the sampling epoch and the trigger point highly developed or postponed from
the start of the epoch to help showing the data on the screen.
E. DISPLAY
The recording are displayed on an oscilloscope. The statistics are
manipulated by digital techniques prior to being displayed in  colour on a VDU.
Latencies and amplitudes can be recorded from the displayed data either
automatically or by cursor measurements.
D. STIMULATION
? VISUAL STIMULATION
? FLASH
The most frequently used is the stroboscope flash. It can be a single  or
repetitive  flash.
E. PATTERNS AND PICTURES
Stationary or changing pattern such as checker board reversal can be used
(Fig 10).
FIG : 10 -CHECKER BOARD
F. ANALYSIS TIME AND RATE
They are available with latencies 70-150msec.
G. DURATION OF SWEEP
They kept at the 250-500ms.
H. ELECTRODE PLACEMENT
Most widely used method for keeping the electrodes is the- 10-20
International System where the head size is used as a parameter (Jasper,
1958)63.  The active electrode (OZ)   located in the midline (Fig 11). The space
above the inion considered as 3-4 cm  in adults which is about  10 % of the
distance connecting the inion and nasion. The reference electrode is placed
12cm from the nasion. The ground electrode is placed in the middle of the
forehead .
FIG:11 -OCCIPITAL SCALP ELECTRODE LOCATIONS
Occipital scalp electrode locations using 10-20 International System.  The
INION is the skull location at the position shown.  The Nasion is on the bridge of the
nose
I. GAZE FIXATION
This procedure needs full cooperation of the individuals. They are
instructed to fix their eye at a centre of the checkerboard. Monocular stimulation
is done by closing the other unstimulated eye with the patch  or any other type
of covering.
2.10.5. NORMAL WAVEFORM OFVEPs
The  VEPs  consists  of  a  series  of  waveforms  of  opposite  polarity.  The
negative wavesare denoted by N and positive waves by P which is  followed by
the  pproximate  latency  in  ms.  The  commonly  seen  waveforms  are  N75,P100and
N145.
? N75 mainly consequences from foveal  area activity  and originates in
primary visual  region 17.
? P100  from the   visual area nineteen (19).
? N145 be a sign of the activity of visual area eighteen (18).
2.10.6. FACTORS  THAT  INFLUENCE VEP
AGE:
The amplitude of P100 is high in infants and children which is almost the
adult value. The adult value is reached in 5-7 years. After 50 years, the
amplitude decreases.
GENDER:
The P100 latency is longer in men, which may be due to bigger head size
in men. The P100 amplitude is greater in women, which may be due to hormonal
influences.
DRUGS:
The drugs that cause miosis (pupillary constriction) like pilocarpine
increases the  P100 latency, which is due to decreased area of retinal
illumination. The use of  mydriatics  decrease P100 latency
EYE DOMINANCE:
The duration  and  amplitude  of  P100 is shorter if recorded by stimulating
the dominant eye compared to the non-dominant eye. This is attributed to the
neuroanatomic asymmetries in the human visual cortex.
EYE MOVEMENTS:
         The P100 amplitude is decreased by eye movements but the latency remains
unaffected.
VISUAL ACUITY:
         With poor visual acuity the amplitude of P100 is decreased but the latency
remains normal.
2.11. LITERATURES: STUDIES  RELEATED  TO  UREMIC
ENCEPHALOPATHY
P.M Rossini   et  al  stated  that the altered latencies and amplitude were
noticed in  53.6% of the  study subjects. Patients on prolonged dialysis showed
elevated levels  of  parameters in visual evoked potential.  Positive correlation
was noticed between  pattern VEP and  blood urea (P < 0.001) .They concluded
that the measurement of  both VEP, blood levels  of uremic markers  was used
as a tool for deduction of   the early  involvement of an encephalopathic
uraemia67 .
E.G Lewis et  al  stated that the altered VEP  recordings was noticed in
both dialysed as well as  in transplanted patients. It showed  prolonged latencies
and altered amplitude  when compared to control groups. They documented that
there  was  no  consistent  connection  between  blood  estimation   and   VEP
parameters in the  correlational investigation 68.
Cosmo L  et  al concluded   that   the  chronic  kidney  disease  individuals
who on medical therapy  may have symptoms range from soft sensorial
clouding to delirium and  even coma. These  complication may be due to
advanced disease itself or by dialysis itself  like dialysis dementia, the dialysis
disequilibrium syndrome, and progressive intellectual dysfunction. Secondary
HyperParathyroidism was noticed in progressive kidney disease in response to
hypocalcemia, also may be a uremic neurotoxin. The  parathyroid hormone can
impose on calcium transport in the brain was evidenced by the research study on
synaptosomes. They explained in the task of parathyroid hormone in the
pathogenesis  of uremic encephalopathy in kidney failure patients69.
Victor Lorenzo et al mentioned about the role of PTH as  a uremic toxin.
Hypocalcemia was encountered in CKD patients can lead to secondary
hyperparathyroidism which  can act as a uremic toxin by altering the cell
calcium levels .Calcium is an input intracellular pointer required for typical cell
function. SHPT  was  begins to start at very  early  stages of  CKD itself. As the
disease progresses, there is a decrease in the number of  vitamin D receptors
(VDR) and  also calciums sensing receptors (CaR) in the parathyroid glands70.
R.  Dyer  et  al mentioned about  the role  of  visual evoked potentials
(VEP) to neurotoxicity research. It showed a significant change in their latency
and amplitude in VEP parameters 71.
Bijen  Nazliel   et  al did their study research  in patients on dialysis by
recording VEP. Nearly  eight study subjects showed prolonged  P100 latency  at
least in one examined eye. They concluded that VEP can be used in CKD
patients to find out the subclinical involvement of central nervous system. They
analysed the consequence of haemodialysis on VEP parameters. They noticed
that there was no correlation between  VEP parameters and dialysis duration,
creatinine, parathyroid hormone, serum blood urea nitrogen (BUN), and
haematocrit levels. They concluded that Visual evoked potential is a reliable,
simple and non-invasive technique that can be used for the analysis and follow
up of subclinical involvement of visual pathways in  those patients 72.
Another study done by A.  Ducati  et  al in CKD children on dialysis.
They noticed  an altered latency and amplitude in VEP . But no corrrelations
was found among blood chemistry markers and VEP parameters. He concluded
that  the  VEP  can  be  taken  as  the  most  amenable  than  EEG  to  distinguish  a
central nervous system (CNS) abnormality in these uremic   patients73.
Tschan  PE  et  al did their research in renal failure patients with many
valuable electrophysiologic and cognition-dependent probes. They concluded
that the altered potentials correlated  directly with the stage of renal failure74.
Giselli   Scaini et al explained about the pathophysiology of uremic
encephalopathy. The  pathophysiology of  uremic encephalopathy till  now is
unsure, but numerous factors has to be  concerned; it is a complex and almost
has a  multi factorial course. Hormonal disturbances, accumulation  of
metabolites, oxidative stress imbalance in excitatory and inhibitory neurotrans-
mitters, and disturbance of the intermediary metabolism have been focused as
causal feature. In spite of uninterrupted therapeutic advancement, the majority
neurological problems of uremia, like uremic encephalopathy, be unsuccessful
to fully reply to dialysis and many are draw out or provoked by dialysis or renal
transplantation. One study   showed that antioxidant therapy could be used as an
adjuvant therapy for the treatment of these neurological complications 75.
Di  Paolo  B  et  al  did VEP,  estimation of urea, creatinine, cholesterol,
triglycerides, lipid electrophoresis, uric acid, glucose, PTH in 29 CKD patients.
Based on their research, they concluded serum PTH has a significant
neurotoxin    role. Because there was a significant direct relationship between
evoked potentials and serum PTH. So they recommended  the VEP recording to
detect preclinical  variation in the central nervous system when there is 40%
renal function.76
Seymen P et  al did the estimation of  VEP in CKD patients  with varied
management  methods. T hey divided 39 study subjects into three groups as
pre-dialysis group, HD group and CAPD group. They observed that there was
prolonged latency in both dialysis groups. There was no significant difference
between VEPs of the CAPD and HD groups. They noticed that the diminished
VEPs demonstrating visual neuronal  damage, when CRF progresses. This study
concluded that the CNS abnormalities  can be analyzed and supplementary
therapeutic modalities could be followed using VEPs during the treatment of
CKD77.
Veysi  Demirbilek et al stated that  the role of VEP as a tool to find out
the subclinical involvement in CKD pediatric patients and looking for a possible
relationship between serum parathyroid hormone (PTH) and creatinine levels
and PR-VEP parameters. They noticed significant alteration in VEP parameters
and a  positive correlation  between VEP results and serum estimation of PTH
and creatinine78.
AIM AND OBJECTIVES
                         3. AIM   AND  OBJECTIVES
Aim:  To evaluate the  subclinical involvement of central nervous system
in  Chronic  kidney  disease  (CKD)  patients   and  analyse   the  association  with
their uremic status.
The objectives of the study
1. To  evaluate  the subclinical involvement of central nervous system in
CKD patients belonging  to stages 3-5 on medical therapy  and  stage 5D
on dialysis by  recording Visual Evoked Potentials(VEP).
2. To measure the  blood levels of uremic markers namely  Urea, Creatinine
and Parathyroid hormone in these patients.
3.  To correlate  the central   nervous system involvement  with the severity
of  their uremic status.
4.  To  assess  the  variation  in   the  CNS  involvement   among  the  two  CKD
groups.
5. To record VEP and measure blood parameters in the age and gender
matched controls.
MATERIALS AND
METHODS
                       4. MATERIALS  AND  METHODS
The research study has been carried out in the  Neuro Physiology
Research Lab, Department  of Physiology, Stanley Medical College, Chennai.
SAMPLE  SIZE :
60 study subjects (30- CKD3-5, 30-CKD5D) and 30 controls.
STUDY DESIGN:
Case-control study
PLACE OF STUDY:
Neuro Physiology Research Lab, Department of Physiology.
SUBJECT GROUP:
30 diagonsed Chronic Kidney Disease(CKD) stage3-5 on medical
treatment, 30 study subjects on stage 5D(on dialysis) who fulfilled the above
norms, were recruited from the Department of Nephrology, Stanley Medical
College Hospital, Chennai.
Regarding the collection of study subjects the following inclusion and
exclusion criteria were followed.
INCLUSION CRITERIA:
         Chronic Kidney Disease (CKD) patients of  both  gender belongs to stage
3-5 on medical treatment, stage 5D (on dialysis-Haemodialysis was only carried
out in nephrology department, Stanley medical college). Staging was done by
the estimated GFR ml/min per 1.73m2 using recommended equation for
calculating GFR with serum creatinine (Pcr), Age, Sex, Body weight.
?     Cockcroft-  Gault formula
Estimated GFR=(140-age) × weight in kg divided by 72 x Pcr  which is
multiply by 0.85 for females.
EXCLUSION CRITERIA:
Acute causes of renal failure, Demyelinating disease like Multiple
sclerosis, Optic neuritis, Ischemic optic neuropathy due to central nervous
system vascualitis, Temporal arteritis, HIV infections, Nutritional optic
neuropathy.
CONTROL  GROUP:
30  Normal   subjects  (control)  age  and  gender  matched   with  study
subjects were recruited from the Master Health Checkup Department in Stanley
Medical College Hospital, Chennai.
ETHICAL  CONSIDERATION:
Ethical  committee approval was obtained from Stanley Medical College,
Chennai for this research study. Informed and written consent was obtained
from the individuals following the thorough method and principle of the study
was clarified to them.
All the practice of recordings, time duration, apparatus were preserved
consistently throughout the study. The study subjects were made to settle down
and comfortable preceding to the test. Thorough history and clinical
examination of the study individuals was done.
METHODOLOGY:
PHYSICAL  AND GENERAL EXAMINATION:
Usual regular height and weight was recorded exclusive of footwear.
VEP RECORDING:
PROCEDURE:
By  means  of  the  typical  RMS  ENMG  EP  MARK  II  apparatus  VEP
recordings were done.
PRE- REQUISITES:
? Avoid hair oil  application after hair wash.
?  If study subjects has refractory error, the normal  routinely used power
glasses are put on throughout  the procedure.
? Avoid  the usage of any miotic or mydriatics drug 12 hours prior to the
procedure
APPARATUS ARRANGEMENT FOR VEP RECORDING:
MONTAGE:
FPz                             -  Reference electrode
Cz                               -  Ground electrode
Oz                               -  Active electrode
APPARATUS  SETUP:
Filter : high filter cut :100-300Hg
Amplification range   : 20000-10000
Sweep duration           : 300 msecs
Number of epochs      : 100 are averaged
Electrode impedence  : less than 5 K?
STIMULATION:
Black and White Checkerboard is  utilized. Contrast -80%, Distance
between  individuals  and  monitor  is  100  cms.  Size  of  pattern  element  -
14×16mintue. Rate of stimulation-4-8 Hz.
METHOD OF RECORDING:
? The study subject was instructed to sit comfortably on a chair with their
footwear.
? Each eye was recorded  separately. The other eye is covered with an eye
shield, with no entry of light into that eye.
? The skin at the point of keeping the electrodes is thoroughly cleaned.
? Three surface disc type electrodes are used-
         Reference, Recording (active) and Ground electrode.
? The active electrode is kept at Oz-5cm above the inion (ridge between the
skull and the back of neck
? The reference electrode is kept at FPz-12 cms from the   nasion (in
between forehead and nose)
? The ground electrode is placed at the middle in forehead.
? The electrodes are linked via the pre amplifier to the cathode ray
oscilloscope.
? The study subjects were guided to fix the gaze at the centre  of the
monitor.
? The lights are switched off.
? The  visual  stimulus  is  send  by  photo  stimulator  at  frequency  of  10
flashes/sec.
? The results  got is showed on the TV monitor and the peak latency and
peak to peak amplitude of the recorded waves are calculated
ESRIMATION    OF    UREMIC   MARKERS      (UREMIC
NEUROTOXIN)
? BLOOOD  UREA
? SERUM   CREATININE
? SERUM   CALCIUM
? SERUM   PHOSPHOROUS
? SERUM   PARATHYROID  HORMONE
Done  in  Biochemistry  Department, Stanley  Medical  College, Chennai.
BLOOD   UREA
METHOD :  Urease  method76
SAMPLE : Unhaemolysed  serum/plasma(heparin)
PROCEDURE : 500?l  reagent mixed with  5?l sample. Read in
semiautonalyser at 340nm after mixed well.
REAGENT COMPOSITION  :  R1- ? Ketoglutarate, urease, Glutamate
dehydrogenase, Adenosine diphosphte, Sodium azide, R2 – NADH
(Nicotinamide adenine dinucleotide reducd, Sodium azide
PRINCIPLE  : The rate of decrease in absorbance of NADH is read at 340nm
and it proportional  to the urea concentration in the sample 77,78.
REFERENCE  RANGE       :  15-39 mg/dl or 2.5-6.4mmol/L79.
SERUM  CREATININE
METHOD                  :  Jaffe’s  kinetic  method80
SAMPLE                   :  Unhaemolysed  serum/plasma(heparin)
PROCEDURE          :    1  ml  of  reagent   mixed  with  0.1  ml  of  sample  and
incubated for 15mints.Reading was done at 520nm.
REAGENT COMPOSITIO: R1- Picric acid reagent
PRINCIPLE        :    Creatinine present in the sample react with picric acid in
alkaline medium forming orange yellow coloured  creatinine picrate. The
absorbance  is measured at 520nm and the intensity is proportional to the
concentration of creatinine in the sample81.
REFERENCE  RANGE  : Male--- 0.7-1.4 mg/dl, Female-- 0.6-1.2 mg/dl79
SERUM  CALCIUM
METHOD                    : O-Cresolphthalein  complexone method
SAMPLE : Unhaemolysed  serum
PROCEDURE           : 500?l  of reagent was added to 12.5 ?l  of
sample and incubated at room temperature for 15 mint.
REAGENT COMPOSITION : AMP buffer PH 10.7,Colour regent- O-
Cresolphthalein  complexone
PRINCIPLE         :   Calcium  fors  a  purple  coloured  complex  with  ortho-
Cresolphthalein Complexone  in an alkaline medium 82,83. Hydrochloric acid
(Hcl) helps to release calcium  bound to proteins and 8 hydroxy quinoline
eliminates the interference magnesium.2 amino-2methyl,1-propanol(AMP)
provides the alkaline medium  for the colour reaction and also act as phosphate
acceptor. The  intensity is measured at 570-580nm.
REFERENCE  RANGE       :  8.5-10.4 mg/dl
SERUM PHOSPHORUS
METHOD                           : UV Molybdate, End point assay.
SAMPLE                            : Fasting  serum sample is preferable.
PROCEDURE                   : 500?l  of reagent was added to 5 ?l  of
sample and incubated at room
temperature for 5 .mint.
REAGENT COMPOSITION:  Molybdate reagent, Sample blan reagent
PRINCIPLE                         : In  acidic medium inorganic phosphorus  reacts
with ammonium molybdate to form phosphomolybdate complex84
 This colorless complex  is measured  at 340nm and is directly
propotional to the concentration of inorganic phosphorus  in the serum sample.
REFERENCE  RANGE       : 2.5- 4.5 mg/dl
SERUM PARATHYROID  HORMONE
This is  done by ECLIA  method .-Electro  Chemiluminescent  Linked
Immuno Assay85.Based on the principle that “ Chemiluminesence is the name
given to light emission produced during a chemical reaction”.
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STATISTICAL ANALYSIS
5. STATISTICAL  ANALYSIS
In  this study research  60  Chronic Kidney Disease (CKD) patients,  30
on medical therapy (CKD3-5) and 30 on  Dialysis(CKD5D)  who fulfilled the
inclusion criteria were  analysed with anthropometric measurements, Visual
Evoked Potential parameters(VEPs), Blood  uremic  markers (uremic toxins
like Blood Urea, Serum Creatinine, Serum Parathyroid hormone(PTH) )levels
among themselves  and  they  are compared with 30 controls.
STATISTICAL TOOLS
The information  collected  concerning  all the preferred  study subjects
were  documented in a Master Chart. With the use of computer by by means of
Epidemiological Information Package (EPI 2010), Statistical Software SPSS 16
and Sigma Stat 3.5 version data analysis was done.
By means of this software range, frequencies, percentages, means,
standard deviations, chi square and 'p'   values  were  calculated  by  One  way
ANOVA and ‘t’ test. Chi-square  test was used to experiment the importance of
disparity  among the  consolidated (quantitative) variables.
 P  -value  <0.001 –Highly significant
and  < 0.05 - significant .
RESULTS
6. RESULTS
From the above study the following results were obtained and analysed.
* COMPARISON OF BASIC PARAMETERS (AGE, SEX, BMI)
BETWEEN CASES AND CONTROL (TABLE1,2)
* COMPARISON  OF   MEAN  VALUES  OF  VEP  PARAMETERS
BETWEEN  CKD  CASES  AND  CONTROL (TABLE: 3)
* COMPARISON OF MEAN VALUES OF UREMIC MARKERS
BETWEEN CASES AND CONTROL (TABLE:4)
* COMPARISON  OF   MEAN  VALUES  OF  VEP  PARAMETERS
BETWEEN  STAGES CKD3-5  AND   CKD 5D PATIENTS
(TABLE: 5)
* COMPARISON  OF  MEAN  VALUES  OF   BLOOD  UREMIC
MARKERS   BETWEEN   CKD  STAGES  3-5   AND   CKD  5D
PATIENTS ( TABLE: 6)
* CORRELATON BETWEEN VEP PARAMETERS AND BLOOD
UREMIC MARKERS (TABLE : 7 - 10)
TABLE – 1
COMPARISON  OF BASIC  PARAMETERS (MEAN±SD) BETWEEN
CKD  CASES  AND  CONTROL.
PARAMETER GROUPS MEAN SD p-Value
AGE CKD3-5 40.67 9.61
0.726CKD5D 39.00 8.36
CONTROL 39.23 8.11
BMI (Wt/htm2) CKD3-5 22.17 2.64
0.985CKD5D 22.27 1.59
CONTROL 22.20 2.54
**-----Highly significant, *  ----- Significant
No  significant difference between study groups and controls.
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No  significant difference between study groups and controls.
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COMPARISON OF BODY MASS INDEX (BMI-MEAN±SD) BETWEEN
CKD  STUDY  GROUPS AND CONTROLS
No  significant difference between study groups and controls.
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TABLE : 2
SEX DISTRIBUTION
GROUP
CKD3-5 CKD5D CONTROL
Chi square
test
N % N % N % p-value
1.000
Not
significant
SEX MALE 16 53.3 16 53.3 16 53.3
FEMALE 14 46.6 14 46.6 14 46.6
TOTAL 30 100 30 100 30 100
**-----Highly significant, *  ----- Significant
No  significant difference between study groups and controls.
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TABLE : 3
 COMPARISON  OF   MEAN  VALUES  OF  VEP  PARAMETERS
BETWEEN  CKD  CASES  AND  CONTROL
PARAMETER EYE GROUPS MEAN SD p-value
N75 RT EYE
CKD3-5 117.95 39.61
0.001**CKD3-5 94.97 35.24
CONTROL 76.83 76.83
LT EYE
CKD3-5 92.39 36.55
0.001**CKD3-5 114.21 41.52
CONTROL 68.57 7.16
P100
RT EYE
CKD3-5 134.29 34.29
0.001**CKD3-5 120.76 31.61
CONTROL 103.78 24.17
LT EYE
CKD3-5 110.54 40.36
0.001**CKD3-5 131.09 41.37
CONTROL 93.67 93.67
N145
RT EYE
CKD3-5 157.16 32.82
0.001**CKD3-5 122.67 37.45
CONTROL 137.23 25.88
LT EYE
CKD3-5 123.11 41.63
0.002*CKD3-5 154.75 44.36
CONTROL 131.02 9.23
P100- N75 RT EYE
CKD3-5 2.83 1.16
0.001**CKD3-5 3.16 1.66
CONTROL 9.35 2.42
LT EYE
CKD3-5 3.17 1.15
0.048*CKD3-5 7.42 15.49
CONTROL 8.73 0.31
**-----Highly significant, *  ----- Significant
Significantly prolonged latency of  VEP parameters (N75 , N145, P100 ) and
reduced amplitude of P100- N75 were observed  in both  groups  of cases when
compared to controls.
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COMPARISON  OF  MEAN VALUES OF  VEP  PARAMETERS-N75
(RIGHT  EYE) BETWEEN  CKD  STUDY GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF  MEAN VALUES OF  VEP  PARAMETERS-P100
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Significant difference between study groups and controls was observed.
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CHART - 6
COMPARISON  OF  MEAN VALUES OF  VEP  PARAMETERS-N145
(RIGHT  EYE) BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF  MEAN VALUES OF  VEP  PARAMETERS-P100-N75
(RIGHT  EYE) BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF  MEAN VALUES OF  VEP  PARAMETERS-N75
(LEFT EYE) BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF  MEAN VALUES OF  VEP  PARAMETERS-P100
(LEFT EYE) BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF  MEAN VALUES OF  VEP  PARAMETERS-N145
(LEFT EYE) BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF  MEAN VALUES OF  VEP  PARAMETERS-P100-N75
(LEFT EYE) BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL
Significant difference between study groups and controls was observed.
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TABLE : 4
COMPARISON  OF   MEAN  VALUES  OF  UREMIC MARKERS
BETWEEN  CKD  CASES AND  CONTROL
PARAMETER GROUPS MEAN SD p-value
UREA
CKD3-5 92.30 43.95
0.001**CKD3-5 145.03 35.40
CONTROL 24.20 0.81
CREATININE
CKD3-5 6.54 0.54
0.001**CKD3-5 5.66 1.13
CONTROL 9.09 0.28
SERUM
CALCIUM
CKD3-5 6.54 0.54
0.001**CKD3-5 5.66 1.13
CONTROL 9.09 0.28
SERUM
PHOSPHOROUS
CKD3-5 4.12 0.43
0.02*CKD3-5 4.01 0.49
CONTROL 3.84 0.13
PTH
CKD3-5 84.70 18.61
0.001**CKD3-5 110.56 30.50
CONTROL 50.00 0.83
**-----Highly significant, *  ----- Significant
 Blood parameters were significantly elevated in patients compared to
controls.
CHART - 12
COMPARISON  OF MEAN VALUES OF  BLOOD UREA (mg/dl)
BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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CHART - 13
COMPARISON  OF MEAN VALUES OF SERUM  CREATININE (mg/dl)
BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF MEAN VALUES OF SERUM  CALCIUM (mg/dl)
BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF MEAN VALUES OF SERUM  PHOSPHOROUS
(mg/dl) BETWEEN  CKD  STUDY  GROUPS  AND  CONTROL.
Significant difference between study groups and controls was observed.
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COMPARISON  OF MEAN VALUES OF SERUM  PARATHYROID
HORMONE  (pg/dl)   BETWEEN  CKD  STUDY  GROUPS  AND
CONTROL.
Significant difference between study groups and controls was observed.
TABLE :  5
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COMPARISON  OF   MEAN  VALUES  OF  VEP  PARAMETERS
BETWEEN   CKD 3-5 AND CKD 5D
PARAMETER EYE GROUPS MEAN SD p-value
N75 RT EYE
CKD3-5 117.95 39.61
0.010*CKD3-5 94.97 35.24
LT EYE
CKD3-5 92.39 36.55
0.017*CKD3-5 114.21 41.52
P100
RT EYE
CKD3-5 134.29 34.29
0.058*CKD3-5 120.76 31.61
LT EYE
CKD3-5 110.54 40.36
0.028*CKD3-5 131.09 41.37
N145
RT EYE
CKD3-5 157.16 32.82
0.001**CKD3-5 122.67 37.45
LT EYE
CKD3-5 123.11 41.63
0.002*CKD3-5 154.75 44.36
P100- N75 RT EYE
CKD3-5 2.83 1.16
0.001**CKD3-5 3.16 1.66
LT EYE
CKD3-5 3.17 1.15
0.048*CKD3-5 7.42 15.49
**-----Highly significant, *  ----- Significant
Significantly prolonged latency of  VEP parameters (N75 , N145, P100) and
reduced amplitude of P100- N75 were observed in CKD stages3-5 compared to
CKD 5D.
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CHART - 18
COMPARISION OF MEAN VALUE OF  VEP PARAMETER- N145 (RT
EYE) BETWEEN CKD3-5 AND CKD5D
CHART - 19
0
20
40
60
80
100
120
140
N75 P100
M
ea
n 
 v
al
ue
COMPARISON OF MEAN VALUES OF  VEP PARAMETER-N75,P100(RT EYE) BETWEEN CKD3-5
AND CKD5D
0
20
40
60
80
100
120
140
160
180
PT-CKD3-5 PT-CKD 5D
COMPARISON OF VEP PARAMETER(RT EYE N145) BETWEEN
CKD3-5 AND CKD5D
PT-CKD3-5
PT-CKD 5D
COMPARISION OFMEAN VALUES OF VEP PARAMETER (RT EYE
P100-N75) BETWEEN CKD3-5 AND  CKD5D
CHART - 20
COMPARISION OF VEP PARAMERTER (N75,P100-LT EYE) BETWEEN
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TABLE : 6
COMPARISION  OF  MEAN  VALUES  OF   BLOOD  UREMIC
MARKERS  BETWEEN  CKD3-5  AND  CKD 5D
PARAMETER GROUPS MEAN SD P-value
B.UREA CKD3-5 92.3 43.95 3.6943
CKD5D 145.03 35.40
Sr. CREATININE CKD3-5 7.0 8.44 0.2001
CKD5D 8.39 2.96
Sr. CALCIUM CKD3-5 6.54 0.54 0.0026*
CKD5D 5.66 1.13
Sr.
PHOSPHOROUS
CKD3-5 3.89 0.16 0.2294
CKD5D 3.87 1.04
Sr.PTH CKD3-5 84.7 18.61 0.0001**
CKD5D 110.56 30.50
**-----Highly significant, *  ----- Significant
Blood parameters were significantly elevated in CKD patients  stage 5D
compared to  stages CKD 3-5.
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BETWEEN  CKD3-5  AND  CKD5D.
5.2
5.4
5.6
5.8
6
6.2
6.4
6.6
6.8
PT-CKD3-5 PT-CKD 5D
COMPARISON  OF MEAN VALUE OF SERUM CALCIUM BETWEEN
CKD3-5,CKD5D
PT-CKD3-5
PT-CKD 5D
3.86
3.865
3.87
3.875
3.88
3.885
3.89
3.895
PT-CKD3-5 PT-CKD 5D
COMPARISON OF MEAN VALUE OF SERUM PHOSPHOROUS
BETWEEN CKD3-5,CKD5D
PT-CKD3-5
PT-CKD 5D
CHART - 27
COMPARISON  OF  MEAN  VALUES  OF  SERUM PARATHYROID
HORMONE (PTH)  BETWEEN  CKD3-5  AND  CKD5D.
CORRELATION   BETWEEN VEP PARAMETERS AND  BLOOD
UREMIC MARKERS (TABLE 7-10)
The following   tables   shows   correlation     between   VEP  Parameters
(N75,P100,N145,P100-N750)  and  Blood uremic markers(Blood urea, Serum
creatinine, Serum Parathyroid hormone )
0
20
40
60
80
100
120
PT-CKD3-5 PT-CKD 5D
COMPARISON OF MEAN VALUE OF SERUM PTH BETWEEN
CKD3-5,CKD5D
PT-CKD3-5
PT-CKD 5D
TABLE : 7
CORRELATION    BETWEEN  N75  AND  BLOOD   UREMIC
MARKERS  IN  CKD3-5  AND  CKD5D
PARAMETER GROUPS
Correlation
coefficient  and
p value
CORRELATION
BETWEEN N75
AND  BLOOD
UREA
RIGHT EYE
CKD3-5 r = -0.016, p =0.02
CKD5D r= -0.219, p=  2.089
LEFT EYE CKD3-5 r= -0.021,P=  0.992
CKD5D r= -0.037,p=    0.005
CORRELATION
BETWEEN N75
AND  SERUM
CREATININE
RIGHT EYE
CKD3-5 r=   0.074, p=  6.190
CKD5D r= -0.028, p=   4.605
LEFT EYE
CKD3-5 r=    0.376,P=7.641
CKD5D r= -0.113, p=   1.884
CORRELATION
BETWEEN N75
AND  SERUM
PTH
RIGHT EYE
CKD3-5 r=  0.317, p= 0.001
CKD5D r= -0.514 ,p=  0.072
LEFT EYE
CKD3-5 r= -0.080, P=  0.309
CKD5D r= -0.141, p=   0.699
CORRELATION  COEFFICIENT  AND  p- VALUE
INTERPRETATION
There was  a  correlation  between N75  and blood uremic markers but it
was not significant.
TABLE - 8
CORRELATION    BETWEEN  P100  AND  BLOOD   UREMIC
MARKERS  IN  CKD3-5  AND  CKD5D
PARAMETER GROUPS Correlation coefficient
and p value
CORRELATION
BETWEEN P100
AND  BLOOD
UREA
RIGHT
EYE
CKD3-5 r =  0.029,p = 0.0001
CKD5D r= 0.149, p= 0.039
LEFT EYE CKD3-5 r= -0.097,p=  0.099
CKD5D r= 0.090,p= 0.234
CORRELATION
BETWEEN P100
AND  SERUM
CREATININE
RIGHT
EYE
CKD3-5 r=   0.039,p=  1.152
CKD5D r= -0.140,p=  2.442
LEFT EYE
CKD3-5 r=  0.236, p=  1.000
CKD5D r= 0.001,p= 3.633
CORRELATION
BETWEEN P100
AND  SERUM
PTH
RIGHT
EYE
CKD3-5 r=  0.194,p=  1.195
CKD5D r= -0.457,p=  0.208
LEFT EYE
CKD3-5 r=  0.075,p=  0.002
CKD5D r= -0.011p= 0.033
CORRELATION  COEFFICIENT  AND  p- VALUE
INTERPRETATION
There was  a  correlation  between P100  and blood uremic markers but it
was not significant.
TABLE : 9
CORRELATION    BETWEEN  N145  AND  BLOOD   UREMIC
MARKERS  IN  CKD3-5  AND  CKD5D
PARAMETER
GROUPS
Correlation
coefficient  and p
value
CORRELATION
BETWEEN N145
AND  BLOOD
UREA
RIGHT
EYE
CKD3-5 r =  -0.172,p =  2.981
CKD5D r =  0.135,p=  0.045
LEFT EYE CKD3-5 r=   0.012,p=   0.001
CKD5D r= -0.200,p=   7.756
CORRELATION
BETWEEN N145
AND  SERUM
CREATININE
RIGHT
EYE
CKD3-5 r= -0.105,p=  1.550
CKD5D r=  0.192,p= 9.764
LEFT EYE
CKD3-5 r= -0.086,p=  2.986
CKD5D r= -0.352,p=  5.984
CORRELATION
BETWEEN N145
AND  SERUM
PTH
RIGHT
EYE
CKD3-5 r=  0.071,p=  8.180
CKD5D r= -0.131,p=   0.134
LEFT EYE
CKD3-5 r=   0.019,p=    6.800
CKD5D r= -0.333,p=  0.014
CORRELATION  COEFFICIENT  AND  p- VALUE
INTERPRETATION
There was a correlation between P100  and blood uremic markers but it
was not significant .
TABLE : 10
CORRELATION    BETWEEN  P100- N75  AND  BLOOD   UREMIC
MARKERS   IN  CKD3-5  AND  CKD5D
PARAMETER GROUPS
Correlation coefficient
and p value
CORRELATION
BETWEEN P100-
N75  AND
BLOOD  UREA
RIGHT
EYE
CKD3-5 r =   0.028,p =5.226
CKD5D r =  0.090,p=9.732
LEFT EYE CKD3-5 r=  0.079,p= 5.709
CKD5D r= -0.037,p= 0.005
CORRELATION
BETWEEN P100-
N75  AND
SERUM
CREATININE
RIGHT
EYE
CKD3-5 r= -0.327,p= 0.011
CKD5D r= -0.026,p=  7.392
LEFT EYE
CKD3-5 r= -0.352,p=  0.019
CKD5D r=  0.271,p=  0.738
CORRELATION
BETWEEN P100-
N75  AND
SERUM  PTH
RIGHT
EYE
CKD3-5 r= -0.164,p= 8.239
CKD5D r=  0.364,p=  3.926
LEFT EYE
CKD3-5 r=  0.088,p=  9.244
CKD5D r= -0.035,p=  3.092
CORRELATION  COEFFICIENT  AND  p-VALUE
INTERPRETATION
There was  a  correlation  between P100  and blood uremic markers but it
was not significant.
DISCUSSION
                                 7. DISCUSSION
All   the   subjects  (both  CKD3-5,CKD5D)   included  in  the  study  had
fulfilled the inclusion criteria .
7.1 CHARACTERISTICS OF STUDY SUBJECTS
The age of the subjects were in the range of 20-60 years for both the
study and control groups. The mean and SD of the subjects were (40.67 ± 9.61)
for CKD3-5, (39.0 ± 8.36) for CKD5D  and (39.23 ± 8.11) for the control
group. The mean age in Derici U  et al, Schindler S et al  and  Toupchizadeh et
al  were almost similar  to that of our study 72,89,90.
The  mean  value for height  of  subjects  were (157.80 ± 3.01) for CKD3-
5,(160.73 ± 4.98) for CKD5D  and (160.5 ± 7.38) for control group. The  mean
value for weight  of  subjects  were  (54.17 ± 5.17) for CKD3-5, (55.37± 5.47)
for CKD5D  and (56.00 ± 6.37) for the control group. The  mean value of  body
mass index(BMI) in the  CKD3-5 group were (22.17±2.64) for CKD5D, (
22.27± 1.59) and (22.20± 2.54) for control group. This was similar to other
studies  like, Toupchizadeh et al with mean value of height (159.80± 3.11),
weight (54.17± 5.17)  and BMI (23.27± 1.69)90. The ratio of the gender in both
the control and study groups were found to be matched.
The patients in the present  study were mostly  in the adult age group.
Henceforth there is a possibility that  the noticeable  VEP parameter changes
and blood estimation of uremic markers are mainly  due to progressive nature
and etiology related rather than  age-related.  This result was found to be similar
as  observed  by  toupchizadeh  at  al90. The observations in our study are
advantageous and  superior than those reported in other studies because the
result was achieved with gender in ratio of 1:1 between the study and control
group unlike  Derici et al, schinder et al with 1.4: 172.
7.2 VISUAL  EVOKED  POTENTIAL STUDY
The subjects without any clinical features of CNS involvement were
chosen. Hence the main parameters that were used in assessing the
abnormalities of  central nervous system were the decreased amplitude and
prolonged  latency   of   VEP  paramerters  (N75,P100,N145,P100-N75)  .  since  the
present study record the early changes that occur  in the  central nervous system
(CNS) caused by  the progressive, irreversible nature of chronic kidney disease
(CKD)  the  abnormalities  observed  in  this  study  subjects  could  be  due  to  the
already mentioned nature of CKD and due to the accumulation of uremic
neurotoxins (uremic  markers).
The   mean  value  of   N75 ,  P100,  N145 was observed with the highly
significant (p0.001)  value with the  mean value of  N75 in the CKD3-5 group
was  (117.95± 39.61), for CKD5D (94.97± 35.24) and for the control group it
was (76.83± 25.37) in the right eye. The mean value in the CKD3-5 group was
(92.39± 36.55), for CKD5D was (114.21±  41.52) and for the control group it
was(  68.57±  7.16)  in  the   left  eye.  With  the  highly  significant   P-value   (P
0.001) in left eye. P100 latency  recorded   in  the  right  eye  was  found  to  be
significantly prolonged in CKD3-5 group (134.29 ± 34.29), CKD5D  (120.76 ±
31.61)  compared with the control group (103.78 ± 24.17) with p 0.001. Also
latency recorded  in the left eye  was observed to be (92.39 ±  36.55)in CKD3-5
group, (114.21 ±  41.52) in CKD5D and for the control group it was ( 68.57±
7.16)  with  a  highly  significant   p-value  0.001.   The   mean  value  of     in  the
CKD3-5 group was (157.16± 32.82), for CKD5D was (122.67± 37.45) and for
the control group it was (137.23± 25.88) in the right eye with the  highly
significant P-value (P <0.001) . The  mean value of  N145  in the CKD3-5 group
was (123.11± 41.63), for CKD5D was(139.24± 53).64 and for the control group
(131.02±  9.23) in the  left eye with the significant P-value (P 0.002). The  mean
value of P100-  N75 in the CKD3-5 group  was (2.83±1.16), for CKD5D (3.16±
1.66) and for the control group ( 9.35± 2.42) in the right eye with the highly
significant  P-value (P<0.001).In left eye with the mean (3.17 ± 1.15), for
CKD5D (7.42 ± 15.49) and for the control group (8.73 ± 0.31) with the
significant  p-value  (P-0.048).
The prolonged latencies  of VEP parameters like N75,P100,N145 and
decreased amplitude of P100-N75 was observed in our study similar to Derici
U et  al where he found altered  P100 latencies  in dialysis patients. The altered
VEP suggests axonal degeneration of central nervous system 72.
According  to   Di  Paolo  B  et  al  who concluded that  it  is  possible  to
sense the CNS complications by various evoked potentials and an elevated
PTH   supporting  my  study. The altered VEP parameters in our study were
suggestive of neural degeneration which correlated well with the uremic status
of the patients76.
Seymen P et al  noticed prolonged latency and altered amplitude of VEP
parameter  in their research. In his study fifty-nine patients diagnosed with CKD
of different etiologies were separated into 3 sets according to the treatment
modalities as pre-dialysis group, HD group and CAPD group. There was no
considerable disparity between VEPs of the CAPD and HD groups. Diminished
VEPs demonstrating visual neuronal system damage were observed, when CRF
progresses. This study concluded that the CNS abnormalities  can be analyzed
and supplementary therapeutic modalities could be followed using VEPs during
the treatment of CRF 77.
Mahnaz Talebi b et al stated  that  in comparison with the control group,
there were exclusively significant prolonged N145 and  P100 latencies  in
hemodialysis and peritoneal dialysis group. He concluded  that optic pathway
can be affected by chronic renal failure and  there would be no marked
difference in optic pathway involvement between patients undergoing
hemodialysis and peritoneal dialysis. This may indicate the equal effects of
hemodialysis and peritoneal dialysis upon subclinical damages of optic
pathway72.  My  study  was  done  only  on  haemodialysis  subjects  where  we
noticed prolonged latencies of P10O ,N75 (P <0.001) and reduced P100
amplitude(P <0.001) 91.
Toupchizadeh Vahideh  et al  in their study showed VEP abnormality
in 35% of hemodialysed patients. They concluded that the etiologic factors
associated with abnormality might be circulating toxins or demyelination.
So  this  research  suggest  that  the  CNS  involvement  could  be  due  to
demyelination or uremic toxins90.
Kuba et al. assessed that there was significant prolonged P100 latency and
decreased P100 amplitude in hemodialysis group, compared to controls .On the
other hand, the outcome of current study established that  there was significant
prolonged P100 latency and decreased P100 amplitude in hemodialysis group,
compared to controls 92 .
7.3 BLOOD  ESTIMATION OF UREMIC MARKERS(UREMIC
NEUROTOXINS)
Due  to  the   progressive  nature  of  CKD,  the  central  nervous  system
complications can be sensed by the estimation of uremic markers(uremic
neurotoxins).The main parameters that were used in assessing the abnormalities
of   central  nervous  system  apart  from  the  evoked  potential   were  the  blood
levels of uremic markers (Blood Urea, Serum creatinine, Serum Parathyroid
hormone(PTH).In order to explain the pathogenesis of secondary
hyperparathyroidism (SHPT) blood levels of serum calcium, serum
phosphorous was estimated.
            The   mean  value  of   Blood   Urea   in  the  CKD3-5  group  was   (92.30±
43.95), for CKD5D (145.03± 35.40) and for the control group  (24.20± 0.8)
with the significant  P-value (P <0.001) . The mean value of  Serum Creatinine
in the CKD3-5 group was  (7.00± 8.44), for CKD5D was (8.39 ± 2.96) and for
the control group  (0.88± 0.05) with the significant P-value (P <0.001). The
mean value of Serum Calcium in the CKD3-5 group was (6.54± 0.54), for
CKD5D (5.66 ± 1.13) and for the control group ( 9.09± 0.28) with the highly
significant P-value (p<0.001) . The mean value of Serum Phosphorous in the
CKD3-5 group was (7.00± 8.4), for CKD5D was (8.39± 2.96) and for the
control group  (0.88± 0.05) with the  significant P-value (P <0.001) . The  mean
value of  Serum  Parathyroid hormone  in the CKD3-5 group was  (84.70±
18.61), for CKD5D (110.56 ± 30.50) and for the control group (50.00 ±
0.83)with the significant  P-value (P <0.001). The  mean value of  Serum
Parathyrid hormone in the CKD3-5 group was (84.70± 18.61), for CKD5D
(110.56±30.50)  and for the control group (50.00 ± 0.83) with the highly
significant  P-value (P <0.001) .
The  mean value of  Blood  Urea in the CKD3-5 group was (92.3±43.95),
for CKD5D was (145.03 ±35.40) with the P value (P 3.69) which is not
significant. The  mean value of  Serum Creatinine in the CKD3-5 group was
(7.0 ±8.44), for CKD5D (8.39 ±2.96) with the P value (P 0.2001) which is not
significant. The  mean value of  Serum calcium in the CKD3-5 group was (6.54
±0.54), for CKD5D (5.66 ±1.13) with the significant P value (P  0.001). The
mean value of  Serum  phosphorous in the CKD3-5 group was (3.89 ±0.16), for
CKD5D (3.87±1.04 ) with the P value (P  0.2294 ) which is not significant. The
mean value of  Serum parathyroid hormone (PTH) in the CKD3-5 group was
(84.7 ±18.61), for CKD5D  (110.56 ± 30.50) with the P value (P - 0.0001 )
which is  highly significant.
M.H. Rahman et al noticed a significant  elevation of PTH (P <0.001),
significantly lowered serum calcium levels (P<0.001), significantly raised
serum phosphorous levels (P <0.001) in ESRD patient. He  concluded  that
increased PTH levels occur even in the beginning path of CRF and progressive
hypocalcemia and hyperphosphatemia are the commencing  factors for the
progress of hyperparathyroidism which concurs with our study.
Cosmo L.Fraser et al, Smogorzewski M, et al, Barbara Rever, MD et al
,Sprague  SM  et  al  stated   that   the   nervous  system   dysfunction   serves  as  a
main  cause  of   morbidity  and  mortality.  They  observed  that  there  was  an
elevated Parathyroid hormone among their study subjects69,94,95,96.
The blood levels of uremic markers (uremic neurotoxins) like urea,
creatinine, parathyroid hormone were elevated in both CKD3-5 on medical
treatment and CKD5D on dialysis compared to controls. When compared
among study groups it was greatly elevated in the CKD5D groups. These
uremic markers along with secondary HPT are more frequently noticed in
progressive CKD which may be challenging to dietary, medical or dialytic
treatment and may even continue subsequent to renal transplantation 33.
There was a positive correlation between VEP parameters
(N75,P100,N145,P100-N75) and blood uremic markers (uremic neurotoxins like
Urea, Creatinine, Parathyroid hormone(PTH) in our study concurring with
Rossini et al and Di Paolo et al67,76.
Thus from this study we end up stating that the subclinical involvement
of central nervous system can be assessed by VEP and uremic markers in
patients with progressive stages of CKD3-5 and CKD5D.
CONCLUSION

8. CONCLUSION
From   this  study  it  is  evident  that  there  is   a  definite   central  nervous
system impairment as shown by the   prolonged latency and reduced amplitude
of   VEP  parameters  N75,P100,N145,P100-N75  in  the  CKD  patients.  In  both  the
CKD groups,  stages 3-5 and stage 5D, there are significant abnormalities in the
VEP recordings. Even though there is  a positive correlation between the VEP
parameters and the severity of uremic status, it is not statistically significant  in
this study.
The subclinical central nervous system   involvement  could be due to the
progressive accumulation of uremic neurotoxins which predispose to the
underlying pathology, axonal degeneration and  demyelination. As the severity
of the disease based on the blood levels of  uremic  toxins correlate with the
VEP  abnormalities  ,  it  is  suggested  that   VEP   can  be  done  as  a  routine
screening tool to detect the early subclinical   involvement of central nervous
system   in  these  patients.   This  will  enable  us  to  plan  for  appropriate
management for preventing eventual development of uremic encephalopathy in
them. Due to the progressive  and irreversible nature of CKD, these  patients
have to be considered for renal transplantation which is better  than medical
treatment or dialysis in improving their uremic status.
Thus it can be concluded, that the routine screening  by recording of
VEP  in CKD patients for neurological involvement  will be  useful in planning
their  effective   management  which  will   reduce   the  morbidity    and  can
improve the  quality of their life.
SUMMARY

9. SUMMARY
This study was conducted to evaluate the central nervous system
involvement  by  recording  VEP in  CKD  patients  ,30 patients   stages3-5 on
medical therapy and 30 patients stage 5D on dialysis. Their   uremic  status was
assessed by the blood levels of uremic markers namely  urea , creatinine and
parathyroid hormone(PTH).These findings were compared with that of a  group
comprising 30 age and gender matched controls.
The altered VEP parameters with prolonged latency of N75,P100,N145 and
reduced  amplitude   of  P100-N75 was noticed in both CKD groups. The blood
levels of uremic markers was elevated significantly when compared to controls.
This suggests that the involvement of central nervous system in these patients.
By recording VEP, we can identify the central nervous system involvement at
an early stage
The  impairment of  the central nervous system correlate with the level of
uremic status which is going to produce the neurological impairment in CKD
patients.
From the results, significant influence of uremic markers and changes in
VEP  proves central nervous system involvement. This study suggests that in
future the recording of  Visual Evoked Potential  may be utilized as a routine
screening test for CKD patients. It  also clearly indicates both study groups
CKD stages 3-5 on medical therapy and stage 5D on dialysis may be considered
for renal transplantation.
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ANNEXURES
PROFORMA
Proforma  for the study subjects:
1.S.No.
2.I.D(given by investigator):
3.Name:
4.Age:
5.Sex:
6.In patient/Out patient:
7.Address&Contact No:
8.Occuption:Not working/Housewife/Professional/Others:
9.Educational Qualification:uneducated/educated
10.Per capita income:Number of family members:     Net family
income:
11.Complaints:
12.Past history:
13.Family history:
14.Social habits:smoker/non-smoker/alcoholic/non- alcoholic
15.Treatment history:
16.General examination:O/E:
Height                       :
Weight                      :
Built                          :
Nourishment             :
BMI                          :
Respiratory rate        :
Pulse rate                  :
Blood pressure         :
Temperature            :
Clinical examination:
17.Investigation:
Blood investigation:
BLOOD UREA                                     -----
SERUM CREATININE                      -----
SERUM CALCIUM                            -----
SERUM PHOSSPHOROUS                ------
SERUM PARATHYROID HORMONE----


MASTER SHEET

CKD STAGES 3 TO 5  ON MEDICAL THERAPY
S.NO AGE SEX HT WT BMI RT  EYE LT  EYE Urea Sr.Cr Ca Po4 PTH
N75 P100 N145 P100-N75 N75 P100 N145 Pioo-N
1 45 M 155 54 32 88.8 118.1 160.6 5.19 157.5 173.1 185.6 5.39 89 5.2 6.8 3.9 99
2 60 M 155 52 23 86.9 100 107.5 6.46 8.75 100 105 2.47 85 3.1 6.7 3.8 89
3 30 M 156 52 23 75 188.8 203.8 3.26 69.4 62.5 96.9 3.8 86 3.2 6.7 3.8 80
4 60 M 154 53 22 195.6 206.9 221.3 2.07 70 81.9 93.1 3 59 2.8 6.8 3.9 125
5 23 M 162 50 20 105.6 119.4 128.1 2.12 101.3 102.5 110 2.94 188 5.2 6.9 3.8 110
6 32 M 162 50 20 100.6 124.4 140.6 4.37 89.4 236.9 266.9 5.67 58 2.8 6.8 3.7 109
7 60 M 156 50 21 205 112.5 226.3 0.96 103.1 90.6 100.6 0.17 58 1.8 6.2 3.8 99
8 45 M 158 50 20 142.5 155 163.1 2.38 105 118.1 126.9 2.5 43 6.3 6.3 3.8 87
9 25 F 154 50 21 106.3 118.1 126.9 3.14 150.1 170.6 181.9 2.92 136 6.8 6.1 4.1 57
10 44 M 162 68 26 108.8 118.1 127.5 2.67 51.9 65 71.3 4.52 100 4.6 6.8 3.9 88
11 45 M 156 56 23 124.4 135 150.6 1.73 130 136.9 142.5 1.88 75 31.2 6.5 3.8 90
12 20 M 156 56 20 157.5 170.6 178.1 2.15 88.1 100.6 115.6 3.39 140 6.7 6.6 3.9 89
13 40 M 156 54 22 105 120 142.5 2.33 62.5 83.1 104.4 4.16 100 3.4 6.7 3.8 88
14 44 M 162 68 26 69.4 82.5 96.9 2.68 33.1 46.9 63.1 4.25 37 1.8 6.8 3.8 67
15 45 F 153 60 24 75.6 104.4 135 4.16 74.4 103.1 130 3.78 180 9.6 6.8 3.9 102
16 40 M 160 55 24 73 96 126 2.59 100 108.9 117.5 4.38 49 3.9 6.9 3.8 56
17 37 F 165 65 24 200.4 224 238 4.03 184 191.3 206.9 2.63 78 1.8 6.9 3.9 60
18 37 F 158 50 24 141.9 154.4 167 4.41 54.4 64.4 71.3 1.61 124 3.8 3.9 4 60
19 36 F 160 50 20 70.6 100 159.4 3 88.8 100 105 2.91 60 1.9 6.6 4.3 56
20 33 M 162 50 20 105.6 119.4 128.1 2.12 101.3 102.5 110 2.94 188 5.2 6.9 3.8 110
21 44 F 158 50 20 142.5 155 163.1 2.38 105 118.1 126.9 2.5 43 6.3 6.3 3.8 87
22 44 M 156 56 20 157.5 170.6 178.1 2.15 88.1 100.6 115.6 3.39 140 6.7 6.6 3.9 89
23 46 F 156 56 23 124.4 135 150.6 1.73 130 136.9 142.5 1.88 75 31.2 6.5 3.8 90
24 35 F 158 50 20 142.5 155 163.1 2.38 105 118.1 126.9 2.5 43 6.3 6.3 3.8 87
25 37 F 160 50 20 70.6 100 159.4 3 88.8 100 105 2.91 60 1.9 6.6 4.3 56
26 37 F 156 54 22 105 120 142.5 2.33 62.5 83.1 104.4 4.16 100 3.4 6.7 3.8 88
27 46 F 156 56 20 157.5 170.6 178.1 2.15 88.1 100.6 115.6 3.39 140 6.7 6.6 3.9 89
28 46 F 156 54 22 105 120 142.5 2.33 62.5 83.1 104.4 4.16 100 3.4 6.7 3.8 88
29 40 F 160 50 20 70.6 100 159.4 3 88.8 100 105 2.91 60 1.9 6.6 4.3 56
30 44 F 156 56 23 124.4 135 150.6 1.73 130 136.9 142.5 1.88 75 31.2 6.5 3.8 90
CKD STAGE 5D ON DIALYSIS
S.NO AGE SEX HT WT BMI RT  EYE LT  EYE Urea  Sr.Cr Ca PO4 PTH
N75 P100 N145 P100-N75 N75 P100 N145 P100N75
1 30 F 156 44 18 44.4 62.1 98.8 4.77 60 83.3 130 63.84 184 11.5 6 3.8 186.4
2 44 M 156 52 21 89.4 108.1 130.6 2.78 126.3 137.5 147.5 1.24 190 12.1 5.9 3.9 120
3 47 F 156 55 23 56.3 73.8 95 2.47 128.1 178.1 2.35 7.28 192 11.9 6.4 3.9 156
4 25 F 156 52 21 90 100.6 112.5 2.67 125 136.3 143.1 2.68 136 6.8 6.3 3.2 86
5 39 F 160 50 20 88.1 100 105.6 7 90 100 106.3 7.08 104 6.8 6.1 3.1 120
6 32 M 156 54 22 106.3 118.1 124.4 1.93 108.8 118.1 130.6 2.47 123 14.3 6.2 3.8 98
7 55 M 156 54 22 70.6 82.5 92.5 2.04 164.4 153.1 143.1 0.94 139 6.8 6.1 3.8 99
8 31 M 156 48 20 65 81.3 113 1.93 210.6 225 240 2.06 136 6.8 6.2 3.2 124
9 32 F 156 56 24 93.8 130 88.1 2.38 123.8 136.3 150.6 4.64 60 10.8 6.5 3.8 124
10 39 M 160 55 22 88.1 100 117.5 2.9 199.4 211.3 232.5 3.05 181 10.3 6.5 3.8 111
11 38 M 160 55 22 155 180 212.5 6.07 130.9 146.9 164.4 1.31 114 9.69 6.8 6.6 134
12 47 F 153 60 24 75.6 104.4 135 4.16 74.4 103.1 130 3.78 180 9.6 6 3.8 156
13 26 M 160 55 23 141.3 153.4 165.6 2.66 105 110.1 126.3 1.48 180 10.2 6 3.9 87
14 37 F 160 55 24 123.8 136.9 147.5 2.83 88.8 100 100.5 2.44 166 8.4 6.2 3.9 88
15 19 M 168 55 20 141.9 152.5 168.8 2.6 80.8 149 169.8 2.92 156 9 6.1 3.1 92
16 36 M 160 55 22 196.9 200.1 214 1.84 75.9 100.9 128.9 2.52 124 10.1 6.8 3.9 85
17 38 F 168 55 22 86.3 130 76 3.9 69.4 81.3 88.8 2.03 104 9.9 6.8 3.9 100
18 35 M 168 55 23 105.6 116.9 131.9 7.5 129 100.3 123 3.82 124 5.2 6.8 3.9 99
19 55 M 168 55 22 72.5 140 90 2.15 121.1 136.4 141 2.29 104 5.8 4.3 5.6 85
20 44 F 168 55 23 89.4 100.6 118.3 6.37 87.5 100.6 105.6 2.7 94 4.6 4.7 3.5 100
21 44 F 168 55 22 71.9 130 96.3 1.31 105.6 117.5 123.8 1.1 104 5.8 4.1 4.2 88
22 40 M 160 55 21 155 159.4 172 2.09 212.4 232 256 9.88 124 5.2 4.1 3.9 86
23 40 M 165 65 24 85 120 118.8 2.12 140 160 176 6.45 124 5.2 3.2 3.6 86
24 44 F 165 65 24 83.1 106.3 154.4 2.09 68.8 99.4 156.9 3 156 6.2 3.2 5.5 88
25 44 M 165 65 24 80 138 66 1.88 69.4 100.6 189 3.76 124 3.2 4.2 4.6 85
26 44 F 165 65 24 125.6 139.9 142.5 1.51 90 81.9 143.1 3.25 156 6.1 3.9 3.9 85
27 44 M 165 65 24 78 135 68 2.8 124.4 135 148.1 2.16 146 3.8 6.8 4.4 86
28 30 F 156 44 20 44.4 139 98.8 4.77 60 83.3 130 63.84 184 11.5 6 3.8 186.4
29 44 M 156 52 24 89.4 108.1 130.6 2.78 126.3 137.5 147.5 1.24 190 12.1 5.9 3.9 120
30 47 F 156 55 23 56.3 73.8 95 2.47 128.1 178.1 2.35 7.28 192 11.9 6.8 3.3 156
CONTROL
S.NO AGE SEX HT WT BMI RT  EYE LT  EYE Urea  Sr.Cr Ca PO4 PTH
N75 P100 N145 P100-N75 N75 P100 N145 P100-N75
1 40 F 153 70 29 66.3 93.8 137.5 8.4 66.4 92.5 126 8.89 24 0.9
8.
9 3.9 50
2 44 M 153 65 27 65 92.5 118.6 10.47 65 91.3 120 8.89 24 0.9 9 4 51
3 47 F 164 66 25 114.4 144.4 196.3 6.92 90 93 135 9.02 26 0.9
9.
2 3.9 51
4 25 M 166 66 24 79.4 139.9 167.4 15.58 67 99 139 8.9 24 0.8
9.
3 3.8 49
5 39 M 166 66 24 127.6 152.5 205 5.73 70 91.3 145 8.9 26 0.9
8.
9 3.8 49
6 32 F 164 62 23 117.5 124.4 135 8.34 69 99 135 9.02 22 0.9 9 3.5 50
7 55 M 152 52 22 168.1 191.3 211.8 8.02 69 100 138 8.89 24 0.9
9.
2 4 49
8 31 F 156 52 21 118.9 130 150 9.9 91.3 113.1 136.3 8.67 26 0.8
9.
3 3.7 49
9 32 M 134 50 21 68.1 88.8 120.6 8.85 86.3 99 139 8.73 24 0.8 9 3.5 50
10 39 F 155 52 22 66.9 92.8 111.3 7.39 69 93.8 135 8.89 26 0.7
9.
2 4 51
11 38 M 160 55 22 66.3 93.8 137.5 7.9 66.4 92.5 135 7.89 24 0.9
8.
9 3.9 49
12 47 M 153 60 24 64.9 92.5 118.7 10.45 65 91.3 120 8.89 24 0.9 9 3.8 50
13 26 F 160 55 21 66.2 93.8 137.5 9.9 66.4 92.5 130 8.79 24 0.9
8.
9 3.7 50
14 37 M 160 55 21 65 92.5 118.8 10.43 65 91.3 120 8.89 24 0.9
9.
9 4 49
15 19 M 168 55 20 66.4 93.8 137.5 0.3 66.4 92.5 139 8.29 24 0.9
8.
9 3.9 49
16 36 F 160 55 22 65 92.5 118.9 10.47 65 91.3 120 8.89 24 0.9 9 3.8 50
17 38 M 168 55 19 66.2 93.8 137.5 8.9 66.4 92.5 140.3 8.92 24 0.9
8.
9 3.9 51
18 35 M 168 48 19 65.1 92.5 118.8 10.47 65 91.3 120 8.89 24 0.9 9 3.8 51
19 55 F 168 55 19 66.1 93.8 137.5 8.6 66.4 92.5 135 9.02 24 0.9
8.
9 3.9 51
20 44 M 168 47 19 64.9 92.5 118.9 10.47 65 91.3 120 8.89 24 0.9 9 3.8 49
21 44 M 168 55 19 66.3 93.8 137.5 10.2 66.4 92.5 143 8.29 24 0.9
8.
9 3.9 49
22 40 F 160 48 21 65 92.5 118.5 10.46 65 91.3 120 8.89 24 0.9
9.
4 3.9 51
23 40 F 165 55 24 66.2 93.8 137.5 10.6 66.4 92.5 143 8.29 24 0.9
8.
9 3.8 50
24 44 F 165 55 24 64.9 92.5 118.7 10.44 65 91.3 120 8.89 24 0.9 9 3.9 51
25 44 M 165 55 24 66.4 93.8 137.5 10.3 66.4 92.5 139 8.29 24 0.9
8.
9 3.7 49
26 44 M 165 55 24 64.8 92.5 118.8 10.46 65 91.3 120 8.89 24 0.9
9.
4 3.9 50
27 44 F 165 65 24 66.3 93.8 137.5 10.5 66.4 92.5 139 8.09 24 0.9
8.
9 3.9 51
28 30 F 156 44 18 65.1 92.5 118.8 10.49 65 91.3 120 8.89 24 0.9 10 3.8 50
29 44 M 156 52 21 66.3 93.8 137.5 8.9 66.4 92.5 139 8.39 24 0.9
8.
9 3.9 50
30 44 F 156 55 23 65.2 92.5 118.8 10.44 65 91.3 120 8.89 24 0.9 9 3.9 51

